FY2025 EPS Estimates for BrainsWay Cut by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY) – HC Wainwright lowered their FY2025 earnings estimates for BrainsWay in a report issued on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.18 per share for the year, down from their previous estimate of $0.32. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.

BrainsWay Stock Performance

BWAY stock opened at $10.18 on Monday. BrainsWay has a one year low of $4.61 and a one year high of $11.79. The company’s fifty day moving average price is $10.28 and its 200-day moving average price is $9.66. The company has a market capitalization of $191.66 million, a PE ratio of 101.81 and a beta of 1.29.

Hedge Funds Weigh In On BrainsWay

Several hedge funds have recently modified their holdings of BWAY. Lazard Asset Management LLC purchased a new position in shares of BrainsWay in the fourth quarter worth $44,000. JPMorgan Chase & Co. increased its position in BrainsWay by 316.3% in the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares during the last quarter. Sei Investments Co. bought a new stake in BrainsWay in the fourth quarter worth $149,000. Cubist Systematic Strategies LLC increased its position in BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares during the last quarter. Finally, Rhumbline Advisers increased its position in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.